110 related articles for article (PubMed ID: 9602695)
1. Increased expression of proliferating cell nuclear antigen in autoimmune hepatitis in a patient with raised serum concentration of CA19-9.
Sohda T; Iwata Y; Shijo H; Egashira Y; Egashira K; Okumura M
J Clin Pathol; 1998 Feb; 51(2):167-9. PubMed ID: 9602695
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues.
Kitagawa Y; Iwai M; Muramatsu A; Tanaka S; Mori T; Harada Y; Okanoue T; Kashima K
Histopathology; 2002 May; 40(5):472-9. PubMed ID: 12010368
[TBL] [Abstract][Full Text] [Related]
3. Normalisation of high CA 19-9 values in autoimmune hepatitis after steroidal treatment.
Montalto M; Santoro L; Vastola M; Curigliano V; Ricci R; Vecchio FM; Manna R; Gasbarrini G
Int J Immunopathol Pharmacol; 2005; 18(3):603-7. PubMed ID: 16164842
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin expression in proliferated bile ductules: the correlation with liver damage in fulminant hepatitis.
Tajiri T; Tate G; Kunimura T; Endo Y; Inoue K; Mitsuya T; Morohoshi T; Yoshiba M
Dig Dis Sci; 2005 Jan; 50(1):188-95. PubMed ID: 15712659
[TBL] [Abstract][Full Text] [Related]
5. Blast-like cell compartment in carcinogen-induced proliferating bile ductules.
Novikoff PM; Yam A; Oikawa I
Am J Pathol; 1996 May; 148(5):1473-92. PubMed ID: 8623918
[TBL] [Abstract][Full Text] [Related]
6. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA.
Maestranzi S; Przemioslo R; Mitchell H; Sherwood RA
Ann Clin Biochem; 1998 Jan; 35 ( Pt 1)():99-103. PubMed ID: 9463746
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma].
Tang X; Zhang J; Chen Y; Lan Z; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):662-6. PubMed ID: 25564055
[TBL] [Abstract][Full Text] [Related]
8. Blood group antigens in the intrahepatic biliary tree. II. Type 1 chain N-acetyllactosamine-related carbohydrate antigens in the proliferated bile ductules.
Jinno K; Moriwaki S; Govindarajan S; Okada Y; Tsuji T
J Hepatol; 1989 May; 8(3):330-7. PubMed ID: 2732447
[TBL] [Abstract][Full Text] [Related]
9. Multicystic biliary hamartoma with extremely elevated CA19-9: a case report.
Morinaga T; Imai K; Yamashita YI; Yamao T; Kaida T; Nakagawa S; Hashimoto D; Chikamoto A; Sumiyoshi S; Mikami Y; Baba H
Scand J Gastroenterol; 2017 Aug; 52(8):916-919. PubMed ID: 28485658
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) in carcinoma at the confluence of the main hepatic ducts and its relationship to expression of CEA, CA19-9 and EGF receptor].
Kawamoto T; Saitou K; Todoroki T; Koike N; Kanazawa N; Iwasaki Y; Nakamura K
Nihon Shokakibyo Gakkai Zasshi; 1993 Feb; 90(2):144-53. PubMed ID: 8096556
[TBL] [Abstract][Full Text] [Related]
11. Bile ductule formation in fetal, neonatal, and infant livers compared with extrahepatic biliary atresia.
Cocjin J; Rosenthal P; Buslon V; Luk L; Barajas L; Geller SA; Ruebner B; French S
Hepatology; 1996 Sep; 24(3):568-74. PubMed ID: 8781326
[TBL] [Abstract][Full Text] [Related]
12. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Sasaki H; Sueda T
J Surg Oncol; 2014 Sep; 110(4):422-9. PubMed ID: 24889968
[TBL] [Abstract][Full Text] [Related]
13. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.
Qin XL; Wang ZR; Shi JS; Lu M; Wang L; He QR
World J Gastroenterol; 2004 Feb; 10(3):427-32. PubMed ID: 14760772
[TBL] [Abstract][Full Text] [Related]
14. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
[TBL] [Abstract][Full Text] [Related]
15. Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China.
Tong Y; Song Z; Zhu W
Clin Chem Lab Med; 2013 Jul; 51(7):1459-66. PubMed ID: 23492572
[TBL] [Abstract][Full Text] [Related]
16. Morphometrical and immunohistochemical study of intrahepatic bile ducts in biliary atresia.
Yamaguti DC; Patrício FR
Eur J Gastroenterol Hepatol; 2011 Sep; 23(9):759-65. PubMed ID: 21694599
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis.
Batheja N; Suriawinata A; Saxena R; Ionescu G; Schwartz M; Thung SN
Mod Pathol; 2000 Dec; 13(12):1265-8. PubMed ID: 11144921
[TBL] [Abstract][Full Text] [Related]
18. Significant role of apoptosis in type-1 autoimmune hepatitis.
Masuichi H; Seki S; Kitada T; Kawada N; Sakaguchi H; Nakatani K; Monna T; Kuroki T
Osaka City Med J; 1999 Jun; 45(1):61-79. PubMed ID: 10723202
[TBL] [Abstract][Full Text] [Related]
19. Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value.
Yamamoto Y; Sugiura T; Todaka A; Okamura Y; Ito T; Ashida R; Kakuda Y; Nakanuma Y; Uesaka K
World J Surg; 2018 Oct; 42(10):3331-3340. PubMed ID: 29619514
[TBL] [Abstract][Full Text] [Related]
20. NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.
Sirica AE; Radaeva S; Caran N
Am J Pathol; 1997 Dec; 151(6):1685-94. PubMed ID: 9403719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
